Empagliflozin 25 mg Tablets
Empagliflozin 25mg
Tablet · Prescription medication
JW Pharmaceutical Corp.
MFDS item code 202102043 · Approved 2021.03.05
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used in conjunction with dietary and exercise regimens to assist in blood sugar control for adults with type 2 diabetes. It may be administered as monotherapy and can be combined with metformin, pioglitazone, sulfonylureas, insulin, or DPP-4 inhibitors if blood sugar control is insufficient. Particular caution should be exercised when used in patients with concomitant cardiovascular disease according to expert guidelines. This medication is effective for improving blood sugar management in individuals with type 2 diabetes.
The recommended dose of this medicine as monotherapy or as add-on combination therapy with other glucose-lowering agents, such as insulin, is 10 mg once daily. If 10 mg of this medicine is well tolerated but additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose of this medicine, take it as soon as you remember. Do not take a double dose on the same day. No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent estimated glomerular filtration rate below 60ml/min/1.73m2 [or CrCl < 60 ml/min], adjust or maintain the dose of this medicine at 10 mg once daily. Discontinue this medicine if the estimated glomerular filtration rate decreases below 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those receiving dialysis, as efficacy is not expected. No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment because it has not been studied in this population. No dose adjustment is necessary based on age. In patients 75 years and older, renal function and the risk of volume depletion should be considered. Initiation of treatment with this medicine is not recommended in adults aged 85 years and older because clinical experience is limited.
This medication is contraindicated for certain patients. For example, individuals with allergies to the active or inactive ingredients should not take this medication. In addition, it is not to be administered to patients with type 1 diabetes or diabetic ketoacidosis. Patients with severely impaired kidney function, i.e., a glomerular filtration rate (GFR) of less than 30 mL/min/1.73m² or patients with end-stage renal disease or on dialysis should not use this medication. This product contains lactose, therefore, patients with lactose intolerance, galactose intolerance, or genetic lactose deficiency should also refrain from using it. Caution should be exercised when administering this medication to patients with mildly impaired kidney function. Patients with a GFR less than 60 mL/min/1.73m² are recommended not to start treatment with this medication, and if already undergoing treatment, the dosage should be adjusted. If the GFR falls below 45 mL/min/1.73m², discontinuation of this medication is advised. In patients with end-stage renal disease or undergoing dialysis, the efficacy of this medication is not expected, hence should not be used. In patients with heart failure of NYHA class I-II, experience with this medication is limited, so caution is necessary, and its use is not recommended in patients of NYHA class III-IV. Furthermore, when used with insulin or sulfonylureas, the risk of hypoglycemia may increase, and therefore dosage reduction of these medications may be needed. During treatment with this medication, various adverse reactions such as hypoglycemia, urinary tract infection, genital infection, increased urination, decreased fluid volume, and changes in kidney function may occur. In particular, hypoglycemia can occur more frequently when used in conjunction with insulin or sulfonylureas, necessitating caution. Rarely, severe metabolic abnormalities known as ketoacidosis may occur, in which case cessation of this medication is required, along with evaluation and treatment from medical personnel. Ketoacidosis may include symptoms such as nausea, vomiting, abdominal pain, and difficulty in breathing. In elderly patients, particularly those over 75 years old, the risk of fluid loss is heightened, and caution should be taken during its use. Serious urinary tract infections, such as urosepsis or pyelonephritis, have been reported, and immediate treatment is necessary upon the onset of infection symptoms. Pregnant women should avoid using this medication, and breastfeeding women are advised to stop breastfeeding upon commencement of this medication. The safety and efficacy of this medication in individuals under 18 years of age have not been established, thus it should not be used in this population. No specific toxic symptoms have been reported in the event of overdose; however, if overdose is suspected, immediate contact with healthcare professionals is necessary for appropriate treatment. When storing this medication, keep it out of the reach of children and it is advised not to transfer it to another container. Caution is especially necessary when driving or operating machinery, particularly due to the risk of hypoglycemia when used with insulin or sulfonylureas. Regular monitoring of kidney function is essential during treatment with this medication, and careful observation of fluid status and electrolyte balance is important. Additionally, this medication may interact with other pharmaceuticals; therefore, consult with a healthcare professional or pharmacist if other medications are currently being taken.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to avoid exposure to air or moisture. It is important to maintain a storage temperature between 1 to 30 degrees Celsius to preserve the drug's potency over time.
Pale yellow, biconvex, oval tablet coated with film
10 tablets/box [(10 tablets/PTP x 1)], 30 tablets/box [(10 tablets/PTP x 3)], 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 25mg
Tablet · Prescription medication
JW Pharmaceutical Corp.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.